This scoping review maps the entire primary evidence base for sertraline therapeutic drug monitoring and finds that most studies detect no concentration-effect relationship, leaving routine TDM unjustified outside select high-risk situations.
📅 Journal publication: 2026(online Jun 29, 2026)·Last updated: Oct 7, 2026
Therapeutic drug monitoring (TDM) could potentially optimize sertraline dosing by linking blood levels to clinical outcomes. The review shows no consistent concentration-effect relationships, though some preliminary evidence suggests non-linear associations for sertraline's efficacy and tolerability. Current evidence does not support routine TDM for sertraline; however, it may be beneficial for certain patients, like those with depression or obsessive-compulsive disorder. Further research is needed to establish clinical benefits of TDM for sertraline.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Canga-Espina C, Bullard JP, Tapia-Alzuguren B, Gędek A, Aubá E, Ortuño F, Aldaz-Pastor A, Molero P
Citation:Canga-Espina C, Bullard JP, Tapia-Alzuguren B, et al. Clinical utility of therapeutic drug monitoring of sertraline: a transdiagnostic systematic scoping review. Frontiers in pharmacology. 2026;17:1812662. doi:10.3389/fphar.2026.1812662
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.